Cancer stem cells, CD200 and immunoevasion

Restifo, 2005, Use of standard criteria for assessment of cancer vaccines, Lancet Oncol., 6, 3, 10.1016/S1470-2045(04)01693-6 Rosenberg, 2004, Cancer immunotherapy: moving beyond current vaccines, Nat. Med., 10, 909, 10.1038/nm1100 Gajewski, 2006, Immune resistance orchestrated by the tumor microenvironment, Immunol. Rev., 213, 131, 10.1111/j.1600-065X.2006.00442.x Kvinlaug, 2007, Targeting cancer stem cells, Expert Opin. Ther. Targets, 11, 915, 10.1517/14728222.11.7.915 Tang, 2007, Prostate cancer stem/progenitor cells: identification, characterization, and implications, Mol. Carcinog., 46, 1, 10.1002/mc.20255 Sell, 2004, Stem cell origin of cancer and differentiation therapy, Crit. Rev. Oncol. Hematol., 51, 1, 10.1016/j.critrevonc.2004.04.007 Pardal, 2003, Applying the principles of stem-cell biology to cancer, Nat. Rev. Cancer, 3, 895, 10.1038/nrc1232 Lapidot, 1994, A cell initiating human acute myeloid leukaemia after transplantation into SCID mice, Nature, 367, 645, 10.1038/367645a0 Al-Hajj, 2007, Cancer stem cells and oncology therapeutics, Curr. Opin. Oncol., 19, 61, 10.1097/CCO.0b013e328011a8d6 Li, 2007, Identification of pancreatic cancer stem cells, Cancer Res., 67, 1030, 10.1158/0008-5472.CAN-06-2030 Ailles, 2007, Cancer stem cells in solid tumors, Curr. Opin. Biotechnol., 18, 460, 10.1016/j.copbio.2007.10.007 Liu, 2007, The prognostic role of a gene signature from tumorigenic breast-cancer cells, N. Engl. J. Med., 356, 217, 10.1056/NEJMoa063994 Bao, 2006, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, 444, 756, 10.1038/nature05236 Zeppernick, 2008, Stem cell marker CD133 affects clinical outcome in glioma patients, Clin. Cancer Res., 14, 123, 10.1158/1078-0432.CCR-07-0932 Zou, 2005, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat. Rev. Cancer, 5, 263, 10.1038/nrc1586 Nathan, 2001, Putting the brakes on innate immunity: a regulatory role for CD200?, Nat. Immunol., 2, 17, 10.1038/83124 Kretz-Rommel, 2007, CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy, J. Immunol., 178, 5595, 10.4049/jimmunol.178.9.5595 Webb, 1984, Localisation of the MRC OX-2 glycoprotein on the surfaces of neurones, J. Neurochem., 43, 1061, 10.1111/j.1471-4159.1984.tb12844.x Barclay, 1986, Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure, Biochem. Soc. Symp., 51, 149 Wright, 2003, Characterization of the CD200 receptor family in mice and humans and their interactions with CD200, J. Immunol., 171, 3034, 10.4049/jimmunol.171.6.3034 Bukovsky, 1983, The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube, Immunology, 48, 587 Hoek, 2000, Down-regulation of the macrophage lineage through interaction with OX2 (CD200), Science, 290, 1768, 10.1126/science.290.5497.1768 Rosenblum, 2004, Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance?, J. Invest. Dermatol., 123, 880, 10.1111/j.0022-202X.2004.23461.x Rosenblum, 2006, CD200, a ‘no danger’ signal for hair follicles, J. Dermatol. Sci., 41, 165, 10.1016/j.jdermsci.2005.11.003 Gorczynski, 2004, Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R, Transplantation, 77, 1138, 10.1097/01.TP.0000121773.18476.1C Gorczynski, 2005, Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R, Transplantation, 79, 1180, 10.1097/01.TP.0000152118.51622.F9 Gorczynski, 1999, An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival, J. Immunol., 163, 1654, 10.4049/jimmunol.163.3.1654 Jenmalm, 2006, Regulation of myeloid cell function through the CD200 receptor, J. Immunol., 176, 191, 10.4049/jimmunol.176.1.191 Cherwinski, 2005, The CD200 receptor is a novel and potent regulator of murine and human mast cell function, J. Immunol., 174, 1348, 10.4049/jimmunol.174.3.1348 Zhang, 2004, Molecular mechanisms of CD200 inhibition of mast cell activation, J. Immunol., 173, 6786, 10.4049/jimmunol.173.11.6786 Siva, 2007, Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200, Cancer Immunol. Immunother., 57, 987, 10.1007/s00262-007-0429-6 Kawasaki, 2007, Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells, Biochem. Biophys. Res. Commun., 364, 778, 10.1016/j.bbrc.2007.10.067 Moreaux, 2008, CD200: a putative therapeutic target in cancer, Biochem. Biophys. Res. Commun., 366, 117, 10.1016/j.bbrc.2007.11.103 Moreaux, 2006, CD200 is a new prognostic factor in multiple myeloma, Blood, 108, 4194, 10.1182/blood-2006-06-029355 Tonks, 2007, CD200 as a prognostic factor in acute myeloid leukaemia, Leukemia, 21, 566, 10.1038/sj.leu.2404559 Gorczynski, 2001, Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice, Clin. Exp. Immunol., 126, 220, 10.1046/j.1365-2249.2001.01689.x Takeuchi, 1997, Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma, Cancer Immunol. Immunother., 43, 375, 10.1007/s002620050347 Filella, 2000, Analysis of type T1 and T2 cytokines in patients with prostate cancer, Prostate, 44, 271, 10.1002/1097-0045(20000901)44:4<271::AID-PROS2>3.0.CO;2-G Lauerova, 2002, Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response, Neoplasma, 49, 159 McWhirter, 2006, Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation, Proc. Natl. Acad. Sci. U. S. A., 103, 1041, 10.1073/pnas.0510081103 Ohyama, 2006, Characterization and isolation of stem cell-enriched human hair follicle bulge cells, J. Clin. Invest., 116, 249, 10.1172/JCI26043 Ossendorp, 1998, Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors, J. Exp. Med., 187, 693, 10.1084/jem.187.5.693 Lowes, 1997, T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas, J. Invest. Dermatol., 108, 914, 10.1111/1523-1747.ep12292705 Aruga, 1997, Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression, J. Leukoc. Biol., 61, 507, 10.1002/jlb.61.4.507 Dalerba, 2007, Cancer stem cells: models and concepts, Annu. Rev. Med., 58, 267, 10.1146/annurev.med.58.062105.204854 Liu, 2006, Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma, Mol. Cancer, 5, 67, 10.1186/1476-4598-5-67 Dean, 2005, Tumour stem cells and drug resistance, Nat. Rev. Cancer, 5, 275, 10.1038/nrc1590